Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-151586 Phase 3 Study in Moderate to Severe Glabellar Lines
2021-003667-10Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2022
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of trenibotulinumtoxinE in glabellar furrowing, sponsored by AbbVie Inc. Primary endpoint: Co-primary efficacy endpoints. Started May 2022; status: completed.
02
Drugs
trenibotulinumtoxinE
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on 2021-003667-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003667-10.